Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label,

Slides:

Advertisements

Similar presentations

Kamyar Kalantar-Zadeh Kidney International

Advertisements

Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for.

Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study Matti.

Extra-Phosphate Load From Food Additives in Commonly Eaten Foods: A Real and Insidious Danger for Renal Patients Omar Benini, DSc, Claudia D’Alessandro,

Alessio Molfino, MD, PhD, George A. Kaysen, MD, PhD, Glenn M

Can Pizza Fit in to the Renal Diet

Cristiane Moraes, PhD, Denis Fouque, PhD, Ana Claudia F

Independent and Joint Associations of Nutritional Status Indicators With Mortality Risk Among Chronic Hemodialysis Patients in the Dialysis Outcomes and.

Revisiting Interdialytic Weight Gain and Mortality Association With Serum Albumin Interactions: The Japanese Dialysis Outcomes and Practice Pattern Study

Can Pizza Fit in to the Renal Diet

A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients.

Jiak Chin Koh, RD, MSc, Winphia Koo, RD, CDE

Impact of Poverty on Serum Phosphate Concentrations in the Third National Health and Nutrition Examination Survey Orlando M. Gutiérrez, MD, MMSc, Tamara.

MyPlate for Healthy Eating With Chronic Kidney Disease (MyPlate Education for Patients With Chronic Kidney Disease Receiving Hemodialysis and Peritoneal.

Chinese Nutrition Educational Materials for Renal Patients

Impact of Vitamin D Status and Obesity on C-Reactive Protein in Kidney-Transplant Patients Bettina Ewers, MSc, Ane Gasbjerg, MSc, Bo Zerahn, MD, Peter.

Extra-Phosphate Load From Food Additives in Commonly Eaten Foods: A Real and Insidious Danger for Renal Patients Omar Benini, DSc, Claudia D’Alessandro,

Early Continuous Renal Replacement Therapy Improves Nutrition Delivery in Neonates During Extracorporeal Life Support Heidi J. Murphy, MD, John B. Cahill,

Volume 86, Issue 3, Pages (September 2014)

Determinants of Plasma Adiponectin Levels in Nondiabetic Subjects With Moderate to Severe Chronic Kidney Disease Luis F. Ramos, MD, Ayumi Shintani, PhD,

Relationship Between Body Mass Index and Mortality in Adults on Maintenance Hemodialysis: A Systematic Review Marietjie Herselman, PhD, Nazeema Esau,

Janeen B. León, MS, RD, LD, Catherine M

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective J. Michael Lazarus, MD, Raymond M. Hakim,

Alessio Molfino, MD, PhD, George A. Kaysen, MD, PhD, Glenn M

Dietary Intake of Patients With Chronic Kidney Disease Entering the LORD Trial: Adjusting for Underreporting Robert G. Fassett, MBBS, Iain K. Robertson,

Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials Suetonia C. Palmer, PhD, Sharon Gardner, MA, Marcello Tonelli,

Artificial Nutritional Support in Chronic Hemodialysis Patients: A Narrative Review Maurizio Bossola, MD, Luigi Tazza, MD, Stefania Giungi, MD, Fausto.

Volume 65, Issue 5, Pages (May 2004)

Volume 54, Issue 2, Pages (August 1998)

Assessing “Low-Carb” Products

Nutrient Non-equivalence: Does Restricting High-Potassium Plant Foods Help to Prevent Hyperkalemia in Hemodialysis Patients? David E. St-Jules, RD, PhD,

Volume 68, Issue 4, Pages (October 2005)

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis Kristian Reich,

Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients Judith Beto, PhD, RDN, FAND, Nisha Bhatt, MD, Teresa.

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia Andrew G. Bostom,

Janeen B. León, MS, RD, LD, Catherine M

Normalization of Protein Intake by Body Weight and the Associations of Protein Intake With Nutritional Status and Survival Srinivasan Beddhu, MD, Nirupama.

2005 NKF clinical meetings abstracts

Nutritional Considerations for Dialysis Vegetarian Patients, Part One

Nutritional Considerations for Dialysis Vegetarian Patients, Part Two

Kamyar Kalantar-Zadeh Kidney International

Let Them Eat During Dialysis: An Overlooked Opportunity to Improve Outcomes in Maintenance Hemodialysis Patients Kamyar Kalantar-Zadeh, MD, MPH, PhD,

Journal of Renal Nutrition

Cristiane Moraes, PhD, Denis Fouque, PhD, Ana Claudia F

Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia Adamasco Cupisti, MD, Claudia D’Alessandro,

Dietary Management of Incremental Transition to Dialysis Therapy: Once-Weekly Hemodialysis Combined With Low-Protein Diet Piergiorgio Bolasco, MD, Adamasco.

Journal of Renal Nutrition

Effect of Omega-3 Fatty Acids on Plasma Level of 8-Isoprostane in Kidney Transplant Patients Mohammad Ramezani, PharmD, PhD, Fatemeh Nazemian, MD, Jamal.

Volume 147, Issue 6, Pages e5 (December 2014)

Journal of Renal Nutrition

Joseph W. Eschbach, John W. Adamson Kidney International

Michael Copland, MD, Paul Komenda, MD, Eric D

Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C

The Effect of Resistance Exercise to Augment Long-term Benefits of Intradialytic Oral Nutritional Supplementation in Chronic Hemodialysis Patients Jie.

Chinese Nutrition Educational Materials for Renal Patients

The calcium–phosphorus in guidelines for CKD-MBD

Estimation of Adipose Pools in Hemodialysis Patients From Anthropometric Measures George A. Kaysen, Peter Kotanko, Fansan Zhu, Shubho R. Sarkar, Steven.

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Drug Dose Adjustments in Patients With Renal Impairment

The value of ferric citrate, an iron-containing phosphate binder, might be different between Japan and the United States Keitaro Yokoyama, Yukio Maruyama,

Trends and Outcomes Associated With Serum Albumin Concentration Among Incident Dialysis Patients in the United States George A. Kaysen, MD, PhD, Kirsten.

The role of daily dialysis in the control of hyperphosphatemia

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

Why measure serum albumin levels?

International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes.

Potential Impact of Nutritional Intervention on End-Stage Renal Disease Hospitalization, Death, and Treatment Costs Eduardo Lacson, MD, T. Alp Ikizler,

Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials Suetonia C. Palmer, PhD, Sharon Gardner, MA, Marcello Tonelli,

Assessing “Low-Carb” Products

The Importance of Sodium Restrictions in Chronic Kidney Disease

Impact of Vitamin D Status and Obesity on C-Reactive Protein in Kidney-Transplant Patients Bettina Ewers, MSc, Ane Gasbjerg, MSc, Bo Zerahn, MD, Peter.

Presentation transcript:

Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study Fumihiko Koiwa, MD, PhD, Keitaro Yokoyama, MD, PhD, Masafumi Fukagawa, MD, PhD, Tadao Akizawa, MD, PhD Journal of Renal Nutrition Volume 27, Issue 5, Pages 346-354 (September 2017) DOI: 10.1053/j.jrn.2017.02.007 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Median changes over time in serum ferritin and box-and-whisker plot showing the 5-number summary of serum ferritin values by maximum dose of PA21 (A), and mean changes in transferrin saturation by maximum dose of PA21 (B). EOT, end of treatment; PA21, sucroferric oxyhydroxide. Journal of Renal Nutrition 2017 27, 346-354DOI: (10.1053/j.jrn.2017.02.007) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Serum phosphorus concentrations and PA21 (sucroferric oxyhydroxide) daily dose. P, phosphorus; EOT, end of treatment; SD, standard deviation. Journal of Renal Nutrition 2017 27, 346-354DOI: (10.1053/j.jrn.2017.02.007) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Serum phosphorus concentrations and phosphate binder daily doses in patients who switched treatment from (A) calcium carbonate (n = 67), (B) lanthanum (n = 24), and (C) combination of calcium carbonate and lanthanum (n = 42) to PA21 (sucroferric oxyhydroxide). CaC, calcium carbonate; P, phosphorus; EOT, end of treatment; SD, standard deviation. Journal of Renal Nutrition 2017 27, 346-354DOI: (10.1053/j.jrn.2017.02.007) Copyright © 2017 The Authors Terms and Conditions

Supplementary Figure 1 Disposition of study participants and flow through the study. Journal of Renal Nutrition 2017 27, 346-354DOI: (10.1053/j.jrn.2017.02.007) Copyright © 2017 The Authors Terms and Conditions

Supplementary Figure 2 Distribution of the number of tablets for daily doses (3 or 6 tablets; percentage) among study participants throughout the study period. EOT, end of treatment. Journal of Renal Nutrition 2017 27, 346-354DOI: (10.1053/j.jrn.2017.02.007) Copyright © 2017 The Authors Terms and Conditions

Supplementary Figure 3 Rates of achievement (percentage) of the target serum phosphorus concentration throughout the study period. EOT, end of treatment. Journal of Renal Nutrition 2017 27, 346-354DOI: (10.1053/j.jrn.2017.02.007) Copyright © 2017 The Authors Terms and Conditions